234 related articles for article (PubMed ID: 11815285)
1. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival.
Grant S; Qiao L; Dent P
Front Biosci; 2002 Feb; 7():d376-89. PubMed ID: 11815285
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.
Badache A; Hynes NE
Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191
[TBL] [Abstract][Full Text] [Related]
3. Stress and radiation-induced activation of multiple intracellular signaling pathways.
Dent P; Yacoub A; Contessa J; Caron R; Amorino G; Valerie K; Hagan MP; Grant S; Schmidt-Ullrich R
Radiat Res; 2003 Mar; 159(3):283-300. PubMed ID: 12600231
[TBL] [Abstract][Full Text] [Related]
4. Cell signalling: growth factors and tyrosine kinase receptors.
Perona R
Clin Transl Oncol; 2006 Feb; 8(2):77-82. PubMed ID: 16632420
[TBL] [Abstract][Full Text] [Related]
5. Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors.
Hamid O
J Am Pharm Assoc (2003); 2004; 44(1):52-8. PubMed ID: 14965154
[TBL] [Abstract][Full Text] [Related]
6. Signaling molecules implicated in heregulin induction of growth arrest and apoptosis.
Guerra-Vladusic FK; Vladusic EA; Tsai MS; Lupu R
Oncol Rep; 2001; 8(6):1203-14. PubMed ID: 11605034
[TBL] [Abstract][Full Text] [Related]
7. The ErbB receptors and their ligands in cancer: an overview.
Normanno N; Bianco C; Strizzi L; Mancino M; Maiello MR; De Luca A; Caponigro F; Salomon DS
Curr Drug Targets; 2005 May; 6(3):243-57. PubMed ID: 15857286
[TBL] [Abstract][Full Text] [Related]
8. ErbB receptor tyrosine kinase inhibitors as therapeutic agents.
Anderson NG; Ahmad T
Front Biosci; 2002 Sep; 7():d1926-40. PubMed ID: 12161338
[TBL] [Abstract][Full Text] [Related]
9. Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells.
Puricelli L; Proietti CJ; Labriola L; Salatino M; Balañá ME; Aguirre Ghiso J; Lupu R; Pignataro OP; Charreau EH; Bal de Kier Joffé E; Elizalde PV
Int J Cancer; 2002 Aug; 100(6):642-53. PubMed ID: 12209601
[TBL] [Abstract][Full Text] [Related]
10. Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis.
Burden S; Yarden Y
Neuron; 1997 Jun; 18(6):847-55. PubMed ID: 9208852
[No Abstract] [Full Text] [Related]
11. MAPK pathways in radiation responses.
Dent P; Yacoub A; Fisher PB; Hagan MP; Grant S
Oncogene; 2003 Sep; 22(37):5885-96. PubMed ID: 12947395
[TBL] [Abstract][Full Text] [Related]
12. The ErbB receptors and their role in cancer progression.
Holbro T; Civenni G; Hynes NE
Exp Cell Res; 2003 Mar; 284(1):99-110. PubMed ID: 12648469
[TBL] [Abstract][Full Text] [Related]
13. Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology.
Pellat A; Vaquero J; Fouassier L
Hepatology; 2018 Feb; 67(2):762-773. PubMed ID: 28671339
[TBL] [Abstract][Full Text] [Related]
14. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
15. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
[TBL] [Abstract][Full Text] [Related]
16. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches.
Zaczek A; Brandt B; Bielawski KP
Histol Histopathol; 2005 Jul; 20(3):1005-15. PubMed ID: 15944951
[TBL] [Abstract][Full Text] [Related]
17. Localization and modulation of ErbB receptor tyrosine kinases.
Carraway KL; Sweeney C
Curr Opin Cell Biol; 2001 Apr; 13(2):125-30. PubMed ID: 11248544
[TBL] [Abstract][Full Text] [Related]
18. Roles of ErbB-3 and ErbB-4 in the physiology and pathology of the mammary gland.
Carraway KL; Carraway CA; Carraway KL
J Mammary Gland Biol Neoplasia; 1997 Apr; 2(2):187-98. PubMed ID: 10882304
[TBL] [Abstract][Full Text] [Related]
19. Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells.
Zi X; Singh RP; Agarwal R
Carcinogenesis; 2000 Dec; 21(12):2225-35. PubMed ID: 11133812
[TBL] [Abstract][Full Text] [Related]
20. ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.
Song X; Fan PD; Bantikassegn A; Guha U; Threadgill DW; Varmus H; Politi K
Cancer Res; 2015 Mar; 75(6):1035-45. PubMed ID: 25596284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
